医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline

2021年06月15日 PM04:03
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Aragen Life Sciences (formerly, GVK BIO), a leading Contract Research and Development Organization (CRDO), head quartered out of Hyderabad, India, announced a strategic partnership with FMC Corporation, a global leader in innovative agricultural science, that provides solutions towards crop protection, plant health, and professional pest and turf management. Through this collaboration, Aragen will support FMC’s global discovery and development needs, including discovery chemistry, discovery biology, and chemical process development.

This partnership is focused on accelerating FMC Corporation’s agro-chemical pipeline. “It has been our privilege to have been able to assist FMC, one of the global leaders in crop science, accelerate its R&D, through this long term partnership. The expansion of this collaboration through all facets of discovery and development is a testimony to the trust and confidence that FMC has in Aragen – we look forward to driving several more success stories for our partner,” said Manni Kantipudi, CEO of Aragen.

Kathleen Shelton, Chief Technology Officer Research and Development at FMC Corporation, on talking about the partnership agreement said, “Aragen has been a valued collaborator of FMC for several years,” said Dr. Kathleen Shelton, Vice President and Chief Technology Officer at FMC. “This partnership extends across multiple disciplines in research and development and we appreciate our strong working relationship.”

About Aragen Life Sciences

Aragen Life Sciences Pvt Ltd (Aragen) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005505/en/

CONTACT

Aragen Life Sciences: Sarat Patanaik, +91 95732 80064, sarat.patanaik@aragen.com

MediaMedic Communications Pvt.Ltd.: Bhavna Pathak, +918830654608, info@mediamedichealth.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 知临集团用于治疗神经母细胞瘤的再利用药物 SACT-1 获得FDA孤儿药资格
  • Charlotte Deane教授加入Exscientia,担任生物制剂人工智能首席科学家
  • シャーロット・ディーン教授がバイオ医薬品AI担当主任科学者としてエクセンシアに参加
  • Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors
  • CDISC Welcomes New Members to Board of Directors